StockData
Natera, Inc. logo

Natera, Inc.

NTRANasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 10/30234% above fair value
$378.92−35.38 (-8.54%)

Close on Nov 2, 2026Market cap $54.62BP/E –Yield –

Natera Qiagen Licensing Remaining Performance Obligations by Year

Qiagen Licensing Remaining Performance Obligations — RPO ($M) [legacy through Q3 2019] ($M)

Natera Qiagen Licensing Remaining Performance Obligations: $40M in FY2018. No newer figure appears in the documents we track.

Latest, FY2018
40
Period ended Dec 31, 2018
Change on a year earlier
–
History
1 years
Since FY2018
Sources
1
Form 10-Q (2022-11-09)

Where the FY2018 figure comes from

Source: Form 10-Q (2022-11-09) ↗

Reported in Form 10-K/10-Q Note — Qiagen Collaboration (2018–2019Q3).

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedQiagen Licensing Remaining Performance Obligations — RPO ($M) [legacy through Q3 2019] ($M)Year on yearSource
FY2018Dec 31, 201840–Form 10-Q (2022-11-09) ↗

Cite this data

StockData. (2026). Natera Qiagen Licensing Remaining Performance Obligations ($M), annual FY2018–FY2018 [Data set]. Compiled from Natera SEC filings and investor materials. https://stockdatahq.com/stocks/ntra/kpis/rpo-qiagen-total

See every metric in the Natera KPI table. Data updated Nov 2, 2026.